journal
MENU ▼
Read by QxMD icon Read
search

Clinical Colorectal Cancer

journal
https://www.readbyqxmd.com/read/28789931/clinical-analysis-of-primary-colorectal-signet-ring-cell-carcinoma
#1
REVIEW
ZhengZi Liang, DengGuo Yan, GuoSheng Li, HaiYu Cheng
The objective of the study was to investigate the clinicopathological features of primary colorectal signet-ring cell carcinoma. We retrospectively analyzed the clinical and survival data of 37 patients with primary colorectal signet-ring cell carcinoma. The mean survival time of patients in stage II, III, and IV were estimated using Student t test and the cumulative survival rates were estimated according to the method of Kaplan-Meier. The significance of the differences in survival rates were calculated using the log rank test...
July 8, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28803718/total-neoadjuvant-therapy-a-shifting-paradigm-in-locally-advanced-rectal-cancer-management
#2
REVIEW
Aaron J Franke, Hiral Parekh, Jason S Starr, Sanda A Tan, Atif Iqbal, Thomas J George
Colorectal carcinoma is the second leading cause of cancer-related deaths in the United States, with rectal cancer accounting for approximately one-third of newly diagnosed cases, thus representing a major socioeconomic health burden. Although minimally invasive procedures (ie, transanal excision) may be appropriate for a subset of patients with small, superficially invasive tumors, a more comprehensive trimodality approach with neoadjuvant chemoradiotherapy, total mesorectal excision, and systemic chemotherapy is recommended for medically operable patients with nonmetastatic, locally advanced rectal cancer (LARC)...
June 27, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28712945/intestinal-and-extraintestinal-cancers-associated-with-inflammatory-bowel-disease
#3
REVIEW
Minna Chang, Liisa Chang, Hanna M Chang, Fuju Chang
Inflammatory bowel disease (IBD) with its 2 most common entities, ulcerative colitis and Crohn's disease, causes an increased risk of developing intestinal cancers. In fact, malignancies are the second most common cause of death after cardiovascular diseases in both sexes of patients with IBD. Risk factors for colorectal cancer in IBD correlate with the duration of the disease, extent of disease, the association with primary sclerosing cholangitis, family history, and early age at onset. Patients with IBD also have an increased risk for developing a variety of extraintestinal malignancies...
June 27, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28734786/clinical-usefulness-of-tools-to-support-decision-making-for-palliative-treatment-of%C3%A2-metastatic-colorectal-cancer-a-systematic-review
#4
Ellen G Engelhardt, Dóra Révész, Hans J Tamminga, Cornelis J A Punt, Mirjam Koopman, Bregje D Onwuteaka-Philipsen, Ewout W Steyerberg, Ilse P Jansma, Henrica C W De Vet, Veerle M H Coupé
BACKGROUND: Decision-making regarding palliative treatment for patients with metastatic colorectal cancer (mCRC) is complex and comprises numerous decisions. Decision-making should be guided by the premise of maintaining and/or improving patients' quality of life, by patient preference, and by the trade-off between treatment benefits and harm. Decision support systems (DSSs) for clinicians (eg, nomograms) can assist in this process. The present systematic review aimed to provide a comprehensive overview of the available DSSs for incurable mCRC and to assess their clinical usefulness...
June 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28797769/all-cause-mortality-in-colorectal-cancer-screening
#5
LETTER
Dan Mayer
No abstract text is available yet for this article.
June 23, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28709877/impact-of-duration-of-neoadjuvant-radiation-on-rectal-cancer-survival-a-real-world-multi-center-retrospective-cohort-study
#6
Omar Abdel-Rahman, Aalok Kumar, Hagen F Kennecke, Caroline H Speers, Winson Y Cheung
BACKGROUND: The utility of neoadjuvant radiotherapy (nRT) for the treatment of stage II and III rectal cancer is well-established. However, the optimal duration of nRT in this setting remains controversial. Using a population-based cohort of patients with stage II and III rectal cancer (RC) treated with curative intent, our aims were to (1) examine the patterns of nRT use and (2) explore the relationship between different nRT schedules and survival in the real-world setting. METHODS: This is a multi-center retrospective cohort study based on population-based data from 5 regional comprehensive cancer centers in British Columbia, Canada...
June 23, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28709876/is-cure-possible-after-sequential-resection-of-hepatic-and-pulmonary-metastases-from-colorectal-cancer
#7
Muthukumarassamy Rajakannu, Pierre Magdeleinat, Eric Vibert, Oriana Ciacio, Gabriella Pittau, Pasquale Innominato, Antonio SaCunha, Daniel Cherqui, Jean-François Morère, Denis Castaing, René Adam
BACKGROUND: Surgical resection is an established therapeutic strategy for colorectal cancer (CRC) metastasis. However, controversies exist when CRC liver and lung metastases (CLLMs) are found concomitantly or when recurrence develops after either liver or lung resection. No predictive score model is available to risk stratify these patients in preparation for surgery, and cure has not yet been reported. PATIENTS AND METHODS: All consecutive patients who had undergone surgery for CLLMs at our institution during a 20-year period were reviewed...
June 23, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28669606/dose-response-effects-of-aerobic-exercise-among-colon-cancer-survivors-a-randomized-phase-ii-trial
#8
Justin C Brown, Andrea B Troxel, Bonnie Ky, Nevena Damjanov, Babette S Zemel, Michael R Rickels, Andrew D Rhim, Anil K Rustgi, Kerry S Courneya, Kathryn H Schmitz
BACKGROUND: Observational studies suggest that higher volumes of physical activity are associated with a lower risk of disease recurrence among survivors of colon cancer. However, the feasibility and safety of prescribing higher volumes of physical activity to survivors of colon cancer are unknown. Furthermore, the pathways through which exercise may reduce disease recurrence are unknown. PATIENTS AND METHODS: Survivors of stage I to III colon cancer were randomized to usual-care control, 150 minutes per week of aerobic exercise (low-dose), or 300 minutes per week of aerobic exercise (high-dose)...
June 17, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28365393/peripheral-neutrophil-to-lymphocyte-ratio-improves-prognostication-in-colon-cancer
#9
Shahrooz Rashtak, Xiaoyang Ruan, Brooke R Druliner, Hongfang Liu, Terry Therneau, Mohamad Mouchli, Lisa A Boardman
BACKGROUND: We studied the role of peripheral neutrophil to lymphocyte ratio (NLR) on survival outcomes in colon and rectal cancer to determine if its inclusion improved prognostication within existing staging systems. PATIENTS AND METHODS: Disease-free (DFS) and overall survival (OS) hazard ratios (HRs) of pretreatment NLR were calculated for 2536 patients with stage I to III colon or rectal cancer and adjusted for age, positive/total number of nodes, T stage, and grade...
June 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28254356/reviewing-the-management-of-obstructive-left-colon-cancer-assessing-the-feasibility-of-the-one-stage-resection-and-anastomosis-after-intraoperative-colonic-irrigation
#10
Gavish Kumar Awotar, Guoxin Guan, Wei Sun, Hongliang Yu, Ming Zhu, Xinye Cui, Jie Liu, Jiaxi Chen, Baoshun Yang, Jianyu Lin, Zeyong Deng, Jianwei Luo, Chen Wang, Osman Abdifatah Nur, Pankaj Dhiman, Pixu Liu, Fuwen Luo
BACKGROUND: The management of obstructive left colon cancer (OLCC) remains debatable with the single-stage procedure of primary colonic anastomosis after cancer resection and on-table intracolonic lavage now being supported. PATIENTS AND METHODS: Patients with acute OLCC who were admitted between January 2008 and January 2015 were distributed into 5 different groups. Group ICI underwent emergency laparotomy for primary anastomosis following colonic resection and intraoperative colonic lavage; Group HP underwent emergency Hartmann's Procedure; Group CON consisted of patients treated by conservative management with subsequent elective open cancer resection; Group COL were colostomy patients; and Group INT consisted of patients who had interventional radiology followed by open elective colon cancer resection...
June 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27825672/survival-impact-of-adjuvant-chemotherapy-for-resected-locally-advanced-rectal-adenocarcinoma
#11
Rebecca Y Tay, Murtaza Jamnagerwalla, Malcolm Steel, Hui-Li Wong, Joseph J McKendrick, Ian Faragher, Suzanne Kosmider, Ian Hastie, Jayesh Desai, Mark Tacey, Peter Gibbs, Rachel Wong
BACKGROUND: Recent data has created uncertainty regarding the benefit of adjuvant fluoropyrimidine-containing chemotherapy following preoperative chemoradiotherapy and surgical resection for locally advanced rectal cancer (LARC). In particular, patients with a pathologic complete response (pCR) may derive no benefit from adjuvant chemotherapy. PATIENTS AND METHODS: This is a retrospective analysis of patients with LARC, diagnosed between January 1, 2003 and December 31, 2014 at 3 Melbourne health services...
June 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27780748/prophylactic-use-of-oral-dexamethasone-to-alleviate-fatigue-during-regorafenib-treatment-for-patients-with-metastatic-colorectal-cancer
#12
Shota Fukuoka, Kohei Shitara, Masaaki Noguchi, Akihito Kawazoe, Yasutoshi Kuboki, Hedeaki Bando, Wataru Okamoto, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino
BACKGROUND: Fatigue is the most common toxicity of all grade toxicities with regorafenib, was the second most common toxicity in the CORRECT (regorafenib monotherapy for previously treated metastatic colorectal cancer) study, and is a major reason for early dose modification. The results from a recent randomized study suggested that dexamethasone (DEX) can improve cancer-related fatigue. PATIENTS AND METHODS: We retrospectively analyzed the effect of prophylactic use of an oral DEX on fatigue during regorafenib treatment in patients with metastatic colorectal cancer (mCRC)...
June 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27670891/exploring-the-prognostic-role-of-microsatellite-instability-in-patients-with-stage-ii-colorectal-cancer-a-systematic-review-and-meta-analysis
#13
Adriana Romiti, Eliana Rulli, Emanuela Pilozzi, Chiara Gerardi, Michela Roberto, Lorenzo Legramandi, Rosa Falcone, Ilaria Pacchetti, Paolo Marchetti, Irene Floriani
BACKGROUND: Many studies have disclosed the prognostic effect of microsatellite instability (MSI) and/or loss of mismatch repair proteins in colorectal cancer. Nevertheless, little evidence supports their role in the decision-making of adjuvant therapy for patients with stage II disease. MATERIALS AND METHODS: The aim of this systematic review was to evaluate the prognostic and/or predictive role of MSI status in patients with stage II colorectal cancer on disease-free survival and overall survival...
June 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28527628/multidisciplinary-clinics-for-colorectal-cancer-care-reduces-treatment-time
#14
Vanessa N Kozak, Alok A Khorana, Sudha Amarnath, Katherine E Glass, Matthew F Kalady
INTRODUCTION: Management of locally advanced and metastatic colorectal cancer (CRC) requires the expertise of multiple specialists. Multidisciplinary clinics (MDCs) are a working model designed to facilitate delivery of coordinated care. The present study evaluated the effects of MDC on the time to treatment (TTT). PATIENTS AND METHODS: Patients with CRC or locally advanced anal cancer who were evaluated at a single-institution MDC from January 2014 to October 2015 were identified from an institutional registry...
April 19, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28465170/treatment-of-patients-with-metastatic-colorectal-cancer-in-a-real-world-scenario-probability-of-receiving-second-and-further-lines-of-therapy-and-description-of-clinical-benefit
#15
Marco Tampellini, Massimo Di Maio, Chiara Baratelli, Lorenzo Anania, Maria Pia Brizzi, Cristina Sonetto, Anna La Salvia, Giorgio Vittorio Scagliotti
BACKGROUND: The optimal therapeutic strategy for metastatic colorectal cancer patients is still a matter of debate. There are no prognostic variables indicating how many lines individual patients ought to receive, and whether later lines could be effective even when earlier ones were not. PATIENTS AND METHODS: We retrospectively collected data from 420 consecutive patients with metastatic colorectal cancer at our institution, describing the proportion of patients who received second or later lines of therapy and the chance of a line of treatment being active when the previous line was not...
April 8, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28687458/effectiveness-of-screening-modalities-in-colorectal-cancer-a-network-meta-analysis
#16
REVIEW
Jianping Zhang, Zhiyuan Cheng, Yubao Ma, Caili He, Yongbin Lu, Yaxue Zhao, Xiaoyu Chang, Yawei Zhang, Yana Bai, Ning Cheng
The aim of the study was to evaluate on the effectiveness of screening modalities in the prevention of colorectal cancer (CRC) occurrence and deaths. General meta-analysis was performed to produce pooled estimates of the effect of CRC incidence and mortality using a search of PubMed, Web of Science, and the Cochrane Library for eligible studies from January 1992 to March 2016. A network meta-analysis was performed to synthetically compare the effectiveness of 5 frequently used screening modalities. A total of 44 studies with a focus on mortality from CRC using different screening methods were included...
April 4, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28454726/predictive-value-of-early-tumor-shrinkage-and-density-reduction-of-lung-metastases-in-patients-with-metastatic-colorectal-cancer-treated-with-regorafenib
#17
Hannes Vanwynsberghe, Xander Verbeke, Johan Coolen, Eric Van Cutsem
INTRODUCTION: The benefit of regorafenib in colorectal cancer is not very pronounced. At present, there is lack of predictive biological or radiological markers. We studied if density reduction or small changes in size of lung metastases could be a predictive marker. METHODS: We retrospectively measured density in size of lung metastases of all patients included in the CORRECT and CONSIGN trials at our center. Contrast-enhanced CT scan at baseline and at week 8 were compared...
March 29, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28433601/volumetric-versus-unidimensional-measures-of-metastatic-colorectal-cancer-in-assessing-disease-response
#18
Meghan G Lubner, Nicholas Stabo, Sam J Lubner, Alejandro Munoz Del Rio, Chihwa Song, Perry J Pickhardt
INTRODUCTION: The purpose of this study was to compare unidimensional (1D/linear) and volumetric (3D) measures of metastatic colorectal cancer (mCRC) at computed tomography (CT) for predicting clinical outcome. PATIENTS AND METHODS: Analysis of CT images in 105 patients (mean age, 59 years; range, 25-81 years; 45 women, 60 men) receiving treatment for mCRC was performed. Both unidimensional and volumetric measures were obtained on index lesions at 3 time points (baseline/midpoint/post-therapy; mean interval, 4...
March 27, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28619608/real-world-direct-health-care-costs-for-metastatic-colorectal-cancer-patients-treated-with-cetuximab-or-bevacizumab-containing-regimens-in-first-line-or-first-line-through-second-line-therapy
#19
Stephen Johnston, Kathleen Wilson, Helen Varker, Elisabetta Malangone-Monaco, Paul Juneau, Ellen Riehle, Sacha Satram-Hoang, Nicolas Sommer, Sarika Ogale
BACKGROUND: The present study examined real-world direct health care costs for metastatic colorectal cancer (mCRC) patients initiating first-line (1L) bevacizumab (BEV)- or cetuximab (CET)-containing regimen in 1L or 1L-through-second-line (1L-2L) therapy. PATIENTS AND METHODS: Using a large US insurance claims database, patients with mCRC initiating 1L BEV- or 1L CET-containing regimen from January 1, 2008 to September 30, 2014 were identified. The per-patient per-month (PPPM) all-cause health care costs (2014 US dollars) were measured during 1L therapy and, for patients continuing to a 2L biologic-containing regimen, 1L-2L therapy...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28456481/significance-of-anemia-in-outcomes-after-neoadjuvant-chemoradiotherapy-for-locally-advanced-rectal-cancer
#20
John M McGrane, David J Humes, Austin G Acheson, Fiona Minear, James M D Wheeler, Catherine J Walter
BACKGROUND: Approximately one quarter of patients receiving neoadjuvant chemoradiotherapy (NCRT) for locally advanced rectal cancer will be anemic at presentation. The outcomes of these anemic patients have historically been less favorable. We assessed the potential of anemia to act as an independent biomarker for a poor prognosis in patients with locally advanced rectal cancer. MATERIALS AND METHODS: We performed a retrospective, observational study of consecutive patients with locally advanced rectal adenocarcinoma who underwent NCRT from 2004 to 2009 at 3 English National Health Service trusts...
March 24, 2017: Clinical Colorectal Cancer
journal
journal
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"